{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-023991","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.029211+00:00","generated_at":"2026-05-15T07:05:09.625889+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026","bullets":["Annual base salary of $525,000; sign-on bonus of $250,000.","Eligible for annual bonus up to 50% of base salary based on board-determined goals.","Board will recommend granting 120,000 stock options and 60,000 restricted stock units.","Marshall, previously Medical Director since Jan 2025, will lead medical strategy and clinical development.","Appointment strengthens leadership as TriSalus advances its PEDD platform for solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-023991","json":"https://secwatch.observer/filing/0001628280-26-023991.json","markdown":"https://secwatch.observer/filing/0001628280-26-023991.md","text":"https://secwatch.observer/filing/0001628280-26-023991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/0001628280-26-023991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/tlsi-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:05:09.625889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}